AMJ Oncology 3 [Supplement 3] . 2026

In this issue

As the treatment landscape in metastatic hormone-sensitive prostate cancer (mHSPC) continues to evolve, ARASEC used an innovative study design to address a setting where an androgen deprivation therapy (ADT)-only control arm was no longer feasible. This AMJ article summarizes key data from the Phase II ARASEC study and explores how its protocol-specified external control arm may help inform future prostate cancer trials.